Stay updated on Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    There are no additions or deletions between the two screenshots. The page content and study details appear unchanged.
    Difference
    0.4%
    Check dated 2025-11-03T01:25:50.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    33 days ago
    Change Detected
    Summary
    Core content updated with a government-status notice and a new software version (v3.2.0); older version tag (v3.1.0) removed.
    Difference
    4%
    Check dated 2025-10-05T10:35:04.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Version bump from v3.0.2 to v3.1.0. This signals a software update; no other content changes are indicated.
    Difference
    0.1%
    Check dated 2025-09-28T03:22:54.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Version updated to v3.0.2 and the Back to Top element was removed; overall content remains otherwise the same.
    Difference
    0.2%
    Check dated 2025-09-13T17:42:10.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-06T15:23:19.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, as well as new content related to Hodgkins lymphoma and various proteins, while removing several terms related to diseases and treatments.
    Difference
    6%
    Check dated 2025-08-30T12:06:06.000Z thumbnail image

Stay in the know with updates to Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.